![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: De Clercq Erik
Publisher: Informa Healthcare
ISSN: 1472-8214
Source: Expert Opinion on Emerging Drugs, Vol.10, Iss.2, 2005-05, pp. : 241-274
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Trends in the Design of Nucleoside Analogues as Anti-HIV Drugs
Current Pharmaceutical Design, Vol. 8, Iss. 8, 2002-04 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
RNA as A Target for Host Defense and Anti-HIV Drugs
Current Drug Targets, Vol. 7, Iss. 12, 2006-12 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Virostatics: A New Class of Anti-HIV Drugs
Current Medicinal Chemistry, Vol. 14, Iss. 2, 2007-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Current Bioactive Compounds, Vol. 1, Iss. 1, 2005-04 ,pp. :